Latest Comments

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

CRISPR: are genetic mutants the future of disease treatment?

CRISPR: are genetic mutants the future of disease treatment?

Hope for sufferers with extremely rare form of liver cancer

Hope for sufferers with extremely rare form of liver cancer

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD conference coverage: How to succeed in late-phase Alzheimer’s research

AD/PD conference coverage: How to succeed in late-phase Alzheimer’s research

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

New class of diabetes drugs show heart failure prevention signal

New class of diabetes drugs show heart failure prevention signal

Positive results from the long-term extension of Nemolizumab in atopic dermatitis

Positive results from the long-term extension of Nemolizumab in atopic dermatitis

Encouraging interim safety data on long-term use of Xeljanz in psoriatic arthritis

Encouraging interim safety data on long-term use of Xeljanz in psoriatic arthritis

Tapinarof poised to fill a void in psoriasis treatment

Tapinarof poised to fill a void in psoriasis treatment

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Persistence may be Novavax’s greatest asset in its quest to develop an RSV vaccine

Persistence may be Novavax’s greatest asset in its quest to develop an RSV vaccine

The importance of real world evidence in the 21st Century Cures Act

The importance of real world evidence in the 21st Century Cures Act

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

PD-1s show early promise in melanoma brain metastases

PD-1s show early promise in melanoma brain metastases

How biomarker-driven cancer immunotherapy can benefit both patients and developers

How biomarker-driven cancer immunotherapy can benefit both patients and developers

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market